Soffer R L, Bandyopadhyay S, Rosenberg E, Hoeprich P, Teitelbaum A, Brunck T, Colby C B, Gloff C
Department of Medicine, Cornell University Medical College, New York, NY 10021.
Proc Natl Acad Sci U S A. 1987 Dec;84(24):9219-22. doi: 10.1073/pnas.84.24.9219.
An octapeptide, TBI-22 (Lys-Gly-Val-Tyr-Ile-His-Ala-Leu), inhibited binding of angiotensin II by a solubilized angiotensin receptor partially purified from rabbit liver. This inhibition appears to result from competition for binding to the same receptor. Radioiodinated TBI-22, like angiotensin II, bound to the solubilized receptor with an affinity such that the binding was inhibited 50% by unlabeled TBI-22 or angiotensin II at nanomolar concentrations. The binding reaction, like that for angiotensin II, required p-chloromercuriphenylsulfonic acid and was reversed in the presence of dithiothreitol. TBI-22 and angiotensin II share the sequence Val-Tyr-Ile-His; this tetrapeptide alone, however, did not inhibit binding of angiotensin II. Replacement of the tyrosine residue by aspartic acid in TBI-22 greatly reduced the ability of the peptide to compete with angiotensin II for binding, suggesting an important contribution of this residue to the configuration required for recognition by the receptor.
一种八肽,TBI - 22(赖氨酸 - 甘氨酸 - 缬氨酸 - 酪氨酸 - 异亮氨酸 - 组氨酸 - 丙氨酸 - 亮氨酸),可抑制从兔肝脏中部分纯化的可溶性血管紧张素受体与血管紧张素II的结合。这种抑制作用似乎是由于对同一受体结合位点的竞争所致。放射性碘化的TBI - 22与血管紧张素II一样,以一定亲和力结合到可溶性受体上,使得在纳摩尔浓度下,未标记的TBI - 22或血管紧张素II能抑制50%的结合。与血管紧张素II的结合反应一样,该结合反应需要对氯汞苯磺酸,并且在二硫苏糖醇存在下可逆转。TBI - 22和血管紧张素II共有缬氨酸 - 酪氨酸 - 异亮氨酸 - 组氨酸序列;然而,仅这个四肽本身并不能抑制血管紧张素II的结合。在TBI - 22中用天冬氨酸取代酪氨酸残基大大降低了该肽与血管紧张素II竞争结合的能力,这表明该残基对受体识别所需构象有重要贡献。